<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02011503</url>
  </required_header>
  <id_info>
    <org_study_id>EFVLU003</org_study_id>
    <nct_id>NCT02011503</nct_id>
  </id_info>
  <brief_title>Use of dHACM in the Treatment of Venous Leg Ulcers</brief_title>
  <official_title>A Randomized Controlled Clinical Trial Evaluating The Application Of Dehydrated Human Amnion/ Chorion Membrane (dHACM) Plus Standard Of Care Vs. Standard Of Care Alone In The Treatment Of Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to evaluate the effectiveness of dehydrated human&#xD;
      amnion/ chorion membrane (dHACM) in reducing time to complete wound closure in patients with&#xD;
      venous leg ulcers (VLUs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">November 30, 2017</completion_date>
  <primary_completion_date type="Actual">August 5, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 100% epithelialization of study ulcer</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in both groups with complete wound healing at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of Quality of Life as assessed by Short Form 36 (SF-36)</measure>
    <time_frame>16 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Crossover Subject Analysis</measure>
    <time_frame>12 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Leg Ulcer</condition>
  <arm_group>
    <arm_group_label>dHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of multi-layer compression therapy with application of dHACM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Application of multi-layer compression therapy without application of dHACM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Multi-layer compression therapy</intervention_name>
    <description>Application of multi-layer compression therapy.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>dHACM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Application of dHACM</intervention_name>
    <description>Application of dHACM to ulcer.</description>
    <arm_group_label>dHACM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Index ulcer characteristics:&#xD;
&#xD;
               1. Full-thickness venous leg ulcer for ≥ 30 days&#xD;
&#xD;
               2. Ulcer area after debridement is ≥ 1 cm² and ≤ 25 cm² at the randomization visit&#xD;
&#xD;
               3. Has a clean, granulating base with minimal adherent slough&#xD;
&#xD;
          2. Subject has completed 14 day run-in period with ≤ 25% wound area reduction&#xD;
             post-debridement.&#xD;
&#xD;
          3. Have one of the following:&#xD;
&#xD;
               -  Ankle Brachial Pressure Index (ABI) &gt; 0.75. (Calculations will be made using&#xD;
                  measurements from both posterior tibial and dorsalis pedis arteries as well as&#xD;
                  both arms) OR&#xD;
&#xD;
               -  Have venous insufficiency confirmed by duplex ultrasound examination for valvular&#xD;
                  or venous incompetence.&#xD;
&#xD;
          4. Age ≥ 18.&#xD;
&#xD;
          5. Females of childbearing potential must be willing to use acceptable methods of&#xD;
             contraception (birth control pills, barriers, or abstinence).&#xD;
&#xD;
          6. Ability to read/understand and sign Informed Consent and Release of Medical&#xD;
             Information Forms.&#xD;
&#xD;
          7. Ability to understand and comply with weekly visits and follow-up regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Index Ulcer Assessment - Index ulcer meeting the following criteria will not be&#xD;
             eligible for enrollment:&#xD;
&#xD;
               1. Penetrates down to muscle, tendon, or bone&#xD;
&#xD;
               2. Presence of another venous ulcer ≤ 2 cm from index ulcer&#xD;
&#xD;
               3. Is deemed by the Investigator to be caused by a medical condition other than&#xD;
                  venous insufficiency&#xD;
&#xD;
               4. Exhibits clinical signs and symptoms of infection&#xD;
&#xD;
               5. If in the opinion of the Investigator, the wound is suspicious for cancer, the&#xD;
                  subject should undergo an ulcer biopsy to rule out carcinoma. If carcinoma is&#xD;
                  ruled out, the subject may be re-screened.&#xD;
&#xD;
               6. Located on the dorsum of the foot or with more than 50% of the ulcer below the&#xD;
                  malleolus&#xD;
&#xD;
          2. Prior therapies - Subjects receiving treatment with any of the following will not be&#xD;
             eligible for enrollment:&#xD;
&#xD;
               1. In the last 7 days - Negative pressure wound therapy of the index ulcer&#xD;
&#xD;
               2. In the last 7 days - Hyperbaric oxygen therapy&#xD;
&#xD;
               3. In the last 30 days - Treatment with cytotoxic chemotherapy, application of&#xD;
                  topical steroids to the ulcer surface, or use of ≥ 14 days of immune-suppressants&#xD;
                  (including systemic corticosteroids); or, subject is anticipated to require such&#xD;
                  medications during the course of the study&#xD;
&#xD;
               4. In the last 30 days - study ulcer treatment with any advanced therapy, including&#xD;
                  EpiFix®, tissue engineered materials (e.g. Apligraf® or Dermagraft®), or other&#xD;
                  scaffold materials (e.g. OASIS® Wound Matrix, MatriStem® Wound Matrix)&#xD;
&#xD;
               5. In the last 30 days - Subject has been on any investigational drug(s) or&#xD;
                  therapeutic device(s)&#xD;
&#xD;
               6. In the last 8 weeks - Amputation or revascularization (surgical or stenting) to&#xD;
                  the affected leg&#xD;
&#xD;
               7. Any history of radiation at the ulcer site&#xD;
&#xD;
               8. Any prior participation in a MiMedx® study&#xD;
&#xD;
               9. Study ulcer has undergone ≥ 12 months of continuous high strength compression&#xD;
                  therapy over its duration&#xD;
&#xD;
          3. Subject criteria that will make subject ineligible for enrollment:&#xD;
&#xD;
               1. Known osteomyelitis or active cellulitis at wound site&#xD;
&#xD;
               2. Hemoglobin A1C &gt;12 in the last 60 days prior to randomization&#xD;
&#xD;
               3. Active malignant disease or subject is less than 1 year disease-free&#xD;
&#xD;
               4. NYHA Class III and IV congestive heart failure (CHF), as defined by the following&#xD;
                  criteria: Class III: Symptoms with moderate exertion; Class IV: Symptoms at rest&#xD;
&#xD;
               5. Auto-immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia,&#xD;
                  Acquired Immunodeficiency Syndrome (AIDS) or HIV&#xD;
&#xD;
               6. Allergy or known sensitivity to Aminoglycosides such as gentamicin sulfate and/or&#xD;
                  streptomycin sulfate&#xD;
&#xD;
               7. Known allergy to the components of the multi-layer compression bandaging, or who&#xD;
                  cannot tolerate MLCT&#xD;
&#xD;
               8. Presence of any condition (including current drug or alcohol abuse, medical or&#xD;
                  psychiatric condition) that is likely to impair understanding of or compliance&#xD;
                  with the study protocol in the judgment of the Investigator&#xD;
&#xD;
               9. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or&#xD;
                  women of childbearing potential who are planning to become pregnant during the&#xD;
                  time of the study OR are unwilling/unable to use acceptable methods of&#xD;
                  contraception (birth control pills, barriers, or abstinence)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Fetterolf, MD</last_name>
    <role>Study Director</role>
    <affiliation>MiMedx Group, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Associated Foot &amp; Ankle Specialists, PC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ILD Research</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Northern California</name>
      <address>
        <city>Mather</city>
        <state>California</state>
        <zip>95655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Veteran's Administration</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Western New York Health Care System</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Research, Inc.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SGM Physicians</name>
      <address>
        <city>Haverford</city>
        <state>Pennsylvania</state>
        <zip>19041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny-Singer Research Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Jennings Bryan Dorn Veterans Affairs Medical Center</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2013</study_first_posted>
  <last_update_submitted>August 22, 2018</last_update_submitted>
  <last_update_submitted_qc>August 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

